Archives
-
BAP1 and the Cellular Logic of Disulfidptosis
2026-10-12
A 2024 Oncogenesis study reports that BAP1 protects cells from disulfidptosis by limiting SLC7A11-associated cystine stress and maintaining a comparatively favorable NADPH-related state. The evidence is strongest in cellular models; human data are correlative, and the mechanism connecting BAP1 to NADPH regulation remains unresolved.
-
BAP1 and the Cellular Logic of Disulfidptosis
2026-10-12
A 2024 Oncogenesis study links BAP1 to protection from disulfidptosis through regulation of SLC7A11 and NADPH balance, while leaving the in vivo and therapeutic significance unresolved.
-
HotStart Universal 2X Green qPCR Master Mix for DFU
2026-10-10
Explore how HotStart Universal 2X Green qPCR Master Mix can support evidence-led interpretation of gene expression in diabetic foot ulcer research. This article connects real-time PCR data with proteomics, histology, immunohistochemistry, and pathway inhibition in a recent bone-transport study.
-
PDK4 Inhibitors: Findings from a 2019 Study
2026-10-09
Lee and colleagues identified a new allosteric pyruvate dehydrogenase kinase 4 inhibitor series by modifying an anthraquinone hit, with compound 8c showing 84 nM in vitro activity and activity across metabolic, allergy, and cancer-related models. The findings support PDK4 as a translationally relevant metabolic target, but the evidence remains preclinical and does not establish clinical efficacy, safety, or applicability beyond the tested models.
-
EZ Cap™ Cas9 mRNA (m1Ψ): A Delivery Framework
2026-10-09
EZ Cap™ Cas9 mRNA (m1Ψ) is examined as more than a nuclease-encoding reagent: it is a transient genome-editing payload whose performance depends on RNA architecture, delivery context, and evidence quality. This article connects Cap1 and m1Ψ design with the cellular drug-delivery framework described in the literature while defining the limits of current interpretation.
-
Acetaminophen: Mechanism, Models, and Evidence
2026-10-08
Explore how Acetaminophen and paracetamol can inform COX-2 pharmacology, oxidative stress, hepatotoxicity research, and ferroptosis interpretation. This evidence-centered analysis also clarifies why small-molecule effects should not be confused with gene-modulating strategies in transthyretin amyloid cardiomyopathy.
-
LC–MS/MS Maps GS-441524 Prodrug Conversion
2026-10-08
A January 2026 Microchemical Journal study used LC–MS/MS to distinguish a novel GS-441524 prodrug, NGP-1, from its released GS-441524 metabolite across gastric, blood, microsomal, and rat pharmacokinetic models. The findings support a multistage conversion model, while remaining preliminary for human pharmacokinetics, intracellular activation, and antiviral efficacy.
-
AT-406 (SM-406): Evidence and Research Context
2026-10-07
AT-406 (SM-406) is an orally bioavailable, multi-IAP antagonist investigated in cancer research as a tool for studying apoptosis pathway activation, chemotherapy sensitization, and tumor-growth responses. This overview separates supplier-reported biochemical and model findings from independently established evidence, compares in vitro and xenograft interpretations, and explains why the supplied Toxoplasma preprint does not validate oncology applications.
-
6-FAM SE: Evidence, Uses and Research Limits
2026-10-07
A source-grounded overview of 6-FAM SE, covering its amine-reactive chemistry, conceptual applications in nucleic-acid and biomolecule research, evidence strength, comparison claims, and the limits of current supplied sources.
-
From Cell Death Signals to Translational Organoids
2026-10-06
How AO/PI phenotyping can strengthen organoid-based drug screening when interpreted as one layer within a broader translational evidence framework.
-
PSI-7977 and Redox Cell-Death Evidence
2026-10-06
PSI-7977 is examined through a scientifically cautious lens alongside new evidence on BAP1, SLC7A11, NADPH, and disulfidptosis. This article clarifies what the 2024 study establishes, what remains unproven, and how to avoid overstating a product-to-pathway connection.
-
PSI-7977 and the Logic of Disulfidptosis
2026-10-05
This evidence-led guide examines PSI-7977 alongside the BAP1–SLC7A11–NADPH framework of disulfidptosis. It clarifies what the 2024 Oncogenesis study demonstrates, what it does not establish about PSI-7977, and how the findings inform responsible translational interpretation.
-
Ginkgo Compounds, Mitochondria, and Yeast Longevity
2026-10-04
A 2026 study used network pharmacology to identify a four-compound Ginkgo biloba cocktail that improved mitochondrial phenotypes and extended chronological lifespan in yeast. The findings support a systems-level, hypothesis-generating approach to multi-component anti-aging research, while remaining limited by the model system and the absence of direct validation in higher organisms.
-
APEX2 Promotes TERT Expression in Human Stem Cells
2026-10-03
A 2024 bioRxiv preprint reports that APEX2, unlike its paralog APEX1, supports efficient TERT expression and telomerase activity in human embryonic stem cells and a melanoma cell line. The study links this effect to APEX2 association with repetitive DNA, particularly MIR sequences within TERT intron 2, while presenting the repair-dependent mechanism as an important hypothesis requiring further validation.
-
MCC950 Sodium: From NLRP3 Signal to Cell State
2026-10-02
MCC950 sodium, also known as CRID3 sodium salt, is a selective pharmacological probe for connecting NLRP3 activation with inflammatory cell-state changes. This article translates recent astrocyte evidence into practical assay design for inflammatory disease research and autoimmune models.